Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection

Mycobacterium abscessus, a rapidly growing nontuberculous mycobacterium, causes chronic pulmonary infections that are difficult to treat due to extensive intrinsic drug resistance. Through high-content screening of 786 FDA-approved drugs against intracellular M. abscessus in human THP-1 macrophages, we identified naftifine, an Antifungal allylamine, as a novel antimycobacterial agent with dual-acting therapeutic mechanisms. Naftifine demonstrated potent activity against reference strains and multidrug-resistant clinical isolates. It showed enhanced efficacy in intracellular environments compared to axenic culture, indicating significant host-directed effects. Mechanistic investigations revealed that naftifine operates through a unique dual mechanism. It directly targets bacteria by inhibiting MmpL3 (MAB_4508), the essential mycolic acid transporter, and modulates host immunity through Autophagy activation via the mTOR pathway suppression. Whole-genome Sequencing of spontaneous naftifine-resistant mutants identified point mutations (S302T and V299G) in MmpL3. Complementation studies confirmed MmpL3 as the primary molecular target. Cross-resistance analysis with Other MmpL3 inhibitors (BM212 and AU1235) validated this target identification. Notably, naftifine represents the first MmpL3 inhibitor demonstrated to induce Autophagy, distinguishing it from Other MmpL3-targeting compounds. Naftifine-induced Autophagy enhanced macrophage-mediated Bacterial clearance and reduced infection-associated necrosis, improving host cell survival. In vivo studies demonstrated a significant reduction of pulmonary and splenic Bacterial burden with reduced lung inflammation. Furthermore, naftifine exhibited synergistic activity with β-lactam Antibiotics without antagonizing Other clinically used Antibiotics. This is the first report demonstrating the unique combination of MmpL3 inhibition and Autophagy induction by a single compound against M. abscessus, establishing naftifine as a promising dual-action therapeutic candidate for treating multidrug-resistant infections.

FDA-approved drugs; MmpL3; Mycobacterium abscessus; naftifine.